Volume 15 - Issue 11 - November 2007

Methicillin-resistant Staphylococcus aureus (MRSA) was first described in the United Kingdom in 1961 shortly after methicillin was introduced.1 Initially, MRSA was associated with hospitalized patients and those possessing established risk factors such as indwelling catheters, previous surgical/wound debridement or antibiotic use, dialysis, intravenous drug use, and immunosuppression.2,3 This pathogen, subsequently termed hospital-acquired MRSA (HA-MRSA), is molecularly distinct from its equally virulent counterpart, community-associated MRSA (CA-MRSA), which is